MicroRNAs: Emerging biomarkers for atrial fibrillation

J Cardiol. 2019 Dec;74(6):475-482. doi: 10.1016/j.jjcc.2019.05.018. Epub 2019 Jul 16.

Abstract

Atrial fibrillation (AF) causes severe cardiac dysrhythmia among patients with cardiovascular diseases. AF increases the risk of stroke and heart failure and is a growing public health concern. AF is also associated with various disease conditions such as hypertension, coronary artery disease, aging, and diabetes mellitus. The mechanism underlying AF is not completely understood due to its complexity. However, experimental and clinical data have revealed that the prevalence of this disease is associated with atrial arrhythmogenic remodeling. Currently, there are no biomarkers that are available for the early diagnosis of AF. Several studies have proposed microRNAs (miRNAs) as useful biomarkers for the diagnosis of AF due to their stability and easy availability both in atrial tissue and circulating blood. miRNAs play an important role in the development of the heart. The dysregulation of miRNA expression is associated with cardiac remodeling. Genetic factors strongly contribute to the pathogenesis of AF. Recently, single nucleotide polymorphisms (SNPs) in various genes and miRNAs have been reported to be associated with AF. The aim of this review was to discuss the correlation between SNPs in miRNAs and AF, including those miRNAs that are commonly reported as potential biomarkers for AF.

Keywords: Atrial fibrillation; Biomarkers; MicroRNA; Single nucleotide polymorphism.

Publication types

  • Review

MeSH terms

  • Atrial Fibrillation / blood*
  • Atrial Fibrillation / physiopathology
  • Atrial Remodeling / genetics
  • Biomarkers / blood
  • Heart Atria / physiopathology
  • Humans
  • MicroRNAs / blood*
  • Polymorphism, Single Nucleotide*

Substances

  • Biomarkers
  • MicroRNAs